Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it

Page 6 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.

• Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/ActionCompletedNCT01439854Not applicableResults posted
• Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsCompletedNCT01422876Phase 3Results posted
• Efficacy and Safety Study of TA-7284 in Patients With Type 2 DiabetesCompletedNCT01413204Phase 3Results posted
• Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and SulfonylureaCompletedNCT01392677Phase 3Results posted
• Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal HyperfiltrationCompletedNCT01392560Phase 2Results posted
• Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusCompletedNCT01387737Phase 3Results posted
• A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a SulphonylureaCompletedNCT01381900Phase 3Results posted
• Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes MellitusCompletedNCT01377844Phase 2Results posted
• Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminCompletedNCT01376557Phase 2Results posted
• 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT01370005Phase 3Results posted
• Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01368081Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin MonotherapyCompletedNCT01340664Phase 2Results posted
• Drug-drug Interaction of Empagliflozin (BI 10773) and MicrogynonCompletedNCT01328184Phase 1Results posted
• Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes MellitusCompletedNCT01316341Phase 1Results posted
• Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusCompletedNCT01306214Phase 3Results posted
• Drug Interaction Study of Digoxin and BI 10773CompletedNCT01306175Phase 1Results posted
• Drug-drug Interaction of Empagliflozin (BI 10773) and SimvastatinCompletedNCT01304329Phase 1Results posted
• Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01294436Phase 3Results posted
• Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01294423Phase 3Results posted
• Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesCompletedNCT01289990Phase 3Results posted
• Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy VolunteersCompletedNCT01284621Phase 1Results posted
• DDI Between BI Empagliflozin (10773) and VerapamilCompletedNCT01276301Phase 1Results posted
• Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 DiabetesCompletedNCT01276288Phase 1Results posted
• A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy SubjectsCompletedNCT01248364Phase 2Results posted
• Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female VolunteersCompletedNCT01242176Phase 1Results posted
• Evaluation of Dapagliflozin Taken Twice-dailyCompletedNCT01217892Phase 3Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With MetforminCompletedNCT01210001Phase 3Results posted
• Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT01195675Phase 1Results posted
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive MedicationCompletedNCT01195662Phase 3Results posted
• Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01193218Phase 2Results posted
• Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of FoodCompletedNCT01189201Phase 1Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01177813Phase 3Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 DiabetesCompletedNCT01167881Phase 3Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT01164501Phase 3Results posted
• Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01159600Phase 3Results posted
• The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)CompletedNCT01137812Phase 3Results posted
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerCompletedNCT01137474Phase 3Results posted
• BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).CompletedNCT01131676Phase 3Results posted
• Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy VolunteersCompletedNCT01111331Phase 1Results posted
• Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver FunctionCompletedNCT01111318Phase 1Results posted
• The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)CompletedNCT01106690Phase 3Results posted
• The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)CompletedNCT01106677Phase 3Results posted
• A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes MellitusCompletedNCT01106651Phase 3Results posted
• The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)CompletedNCT01106625Phase 3Results posted
• Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)CompletedNCT01096667Phase 2Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneCompletedNCT01095666Phase 3Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and ExerciseCompletedNCT01095653Phase 3Results posted
• The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) TrialCompletedNCT01081834Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01064414Phase 3Results posted
• Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)CompletedNCT01059825Phase 2Results posted
• Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)CompletedNCT01054300Phase 1Results posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular DiseaseCompletedNCT01042977Phase 3Results posted
• CANVAS - CANagliflozin cardioVascular Assessment StudyCompletedNCT01032629Phase 3Results posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and HypertensionCompletedNCT01031680Phase 3Results posted
• Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes MellitusCompletedNCT01029704Phase 2Results posted
• An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesCompletedNCT01022112Phase 2Results posted
• Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT01011868Phase 2Results posted
• Dapagliflozin DPPIV Inhibitor add-on StudyCompletedNCT00984867Phase 3Results posted
• Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 DiabetesCompletedNCT00976495Phase 2Results posted
• Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT00972244Phase 2Results posted
• CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideCompletedNCT00968812Phase 3Results posted
• Study of LX4211 in Subjects With Type 2 Diabetes MellitusCompletedNCT00962065Phase 2Results posted
• 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)CompletedNCT00885118Phase 2Results posted
• Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label ExtensionCompletedNCT00881530Phase 2Results posted
• Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 DiabetesCompletedNCT00859898Phase 3Results posted
• Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 DiabetesCompletedNCT00855166Phase 3Results posted
• Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 DiabetesCompletedNCT00831779Phase 2Results posted
• 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic PatientsCompletedNCT00789035Phase 2Results posted
• BI 10773 add-on to Metformin in Patients With Type 2 DiabetesCompletedNCT00749190Phase 2Results posted
• Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 DiabetesCompletedNCT00736879Phase 3Results posted
• Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic PatientsCompletedNCT00707954Phase 1/2Results posted
• Add-on to Thiazolidinedione (TZD) FailuresCompletedNCT00683878Phase 3Results posted
• Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes PatientsCompletedNCT00680745Phase 3Results posted
• Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on InsulinCompletedNCT00673231Phase 3Results posted
• Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal ImpairmentCompletedNCT00663260Phase 2/3Results posted
• Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes PatientsCompletedNCT00660907Phase 3Results posted
• A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have DiabetesCompletedNCT00650806Phase 2Results posted
• An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release TabletsCompletedNCT00643851Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesCompletedNCT00642278Phase 2Results posted
• A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes MellitusCompletedNCT00575159Phase 2Results posted
• 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 DiabetesCompletedNCT00558571Phase 1Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneCompletedNCT00528879Phase 3Results posted
• A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and ExerciseCompletedNCT00528372Phase 3Results posted
• Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)CompletedNCT00500331Phase 2Results posted
• Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-NaiveCompletedNCT00495469Phase 2Results posted
• A Pilot Study of BMS-512148 in Subjects With Type 2 DiabetesCompletedNCT00357370Phase 2/3Results posted
• Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver DiseaseCompletedNCT07881796Not applicable
• A Study in Type 2 Diabetes Patients Who Are Taking Moderate Dose Insulin, Looking at the Effects of the Medication Luseogliflozin on Risk of Ketoacidosis and Insulin Resistance.CompletedNCT07876258Phase 3
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07872358Phase 1
• ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingCompletedNCT07871799Phase 2
• Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²CompletedNCT07866235Not applicable
• Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/DapagliflozinCompletedNCT07754331Phase 1
• SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD)Active, not recruitingNCT07694596Not applicable
• Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mgCompletedNCT07694115Phase 1
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07691203Phase 1
• Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus NephritisActive, not recruitingNCT07678203Phase 1/2
• SGLT2 Adjunct in T1DCompletedNCT07591077Phase 2/3
• Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic SyndromeCompletedNCT07563647Phase 4
• Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.CompletedNCT07556094Not applicable
• Dapagliflozin in Living-Donor Kidney Transplant RecipientsActive, not recruitingNCT07555106Phase 2

← Sodium-Glucose Transporter 2 Inhibitors overview